Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $711.26 | 38 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $147.53 | 5 | $0 (2017) |
| Celgene Corporation | $115.38 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $47.20 | 3 | $0 (2017) |
| Astellas Pharma US Inc | $46.99 | 3 | $0 (2018) |
| Janssen Biotech, Inc. | $38.01 | 3 | $0 (2017) |
| PFIZER INC. | $33.38 | 3 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $27.12 | 2 | $0 (2017) |
| Gilead Sciences Inc | $26.37 | 2 | $0 (2017) |
| AbbVie, Inc. | $23.82 | 1 | $0 (2017) |
| Kyowa Kirin, Inc. | $22.45 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $11.44 | 1 | Kyowa Kirin, Inc. ($11.44) |
| 2018 | $86.11 | 6 | Astellas Pharma US Inc ($46.99) |
| 2017 | $613.71 | 31 | E.R. Squibb & Sons, L.L.C. ($147.53) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 2 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/06/2017 | PFIZER INC. | BOSULIF (Drug), SUTENT, BAVENCIO | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/03/2017 | Kyowa Kirin, Inc. | SANCUSO (Drug), FARESTON, IXEMPRA | Food and Beverage | In-kind items and services | $11.01 | General |
| Category: ANTIEMETIC - 5HT3 INHIBITOR | ||||||
| 03/23/2017 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: BioOncology | ||||||
| 03/22/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $7.15 | General |
| Category: Oncology | ||||||
| 03/17/2017 | MEDIVATION INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: ONCOLOGY | ||||||
| 02/28/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: Oncology | ||||||
| 02/24/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $12.13 | General |
| 02/24/2017 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $10.71 | General |
| Category: Anemia | ||||||
| 02/23/2017 | PFIZER INC. | INLYTA (Drug), SUTENT, XALKORI | Food and Beverage | In-kind items and services | $10.89 | General |
| Category: ONCOLOGY | ||||||
| 02/17/2017 | PFIZER INC. | SUTENT (Drug), XALKORI, INLYTA | Food and Beverage | In-kind items and services | $11.62 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 02/09/2017 | Eisai Inc. | Halaven (Drug) | Food and Beverage | Cash or cash equivalent | $15.20 | General |
| Category: Oncology | ||||||
| 01/27/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $9.62 | General |
| Category: Cardiovascular | ||||||
| 01/20/2017 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 44 | 51 | $8,690 | $2,825 |
| 2021 | 4 | 72 | 541 | $23,495 | $6,727 |
| 2020 | 1 | 12 | 12 | $660.00 | $136.55 |
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 11 | 12 | $4,740 | $1,311 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 19 | $2,850 | $1,296 | 45.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 15 | 20 | $1,100 | $217.30 | 19.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2021 | 12 | 480 | $13,440 | $3,158 | 23.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 24 | $3,600 | $1,764 | 49.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 12 | 13 | $5,135 | $1,532 | 29.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 24 | 24 | $1,320 | $273.12 | 20.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 12 | 12 | $660.00 | $136.55 | 20.7% |
About Dr. James May, M.D
Dr. James May, M.D is a Hematology & Oncology healthcare provider based in North Chesterfield, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033172994.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James May, M.D has received a total of $711.26 in payments from pharmaceutical and medical device companies, with $11.44 received in 2019. These payments were reported across 38 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($711.26).
As a Medicare-enrolled provider, May has provided services to 128 Medicare beneficiaries, totaling 604 services with total Medicare billing of $9,688. Data is available for 3 years (2020–2022), covering 8 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location North Chesterfield, VA
- Active Since 04/10/2006
- Last Updated 05/21/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1033172994
Products in Payments
- Revlimid (Drug) $115.38
- SPRYCEL (Drug) $107.69
- XTANDI (Drug) $59.78
- INJECTAFER (Drug) $47.20
- IMBRUVICA (Drug) $38.01
- OPDIVO (Biological) $30.22
- Venclexta (Drug) $23.82
- ENTELLUS - XPRESS ENT DILATION SYSTEM (Device) $20.61
- Stivarga (Drug) $18.92
- SYNDROS (Drug) $18.21
- XARELTO (Drug) $17.33
- Halaven (Drug) $15.20
- PROMACTA (Drug) $14.40
- FASLODEX (Drug) $14.36
- VARUBI (Drug) $12.88
- RYDAPT (Drug) $12.72
- JAKAFI (Drug) $11.83
- SUTENT (Drug) $11.62
- POTELIGEO (Drug) $11.44
- Perjeta (Biological) $11.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.